Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
Project description
PI: Landi Lorenza.
Other IRE Principal Collaborators: Nisticò Paola, Di Modugno Damiani Francesca Romana, Blandino Giovanni, Minuti Gabriele, Porciello Nicla, Baldari Silvia
Project duration: 24 months
Project code: PNRR-MCNT1-2023-12377772
The project, titled "Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)", investigates the role of metabolic dysregulation in the tumor microenvironment (TME) and its impact on immunotherapy outcomes. Specifically, the project focuses on the metabolic rewiring of tumor cells, immune cells, and cancer-associated fibroblasts in NSCLC patients treated with immune checkpoint inhibitors (ICIs). By leveraging advanced technologies, such as digital spatial profiling and ex vivo models like tissue slices and patient-derived organoids, the study aims to identify metabolic signatures linked to therapy response.
Purpose
The primary objective is to discover and validate metabolic biomarkers that can predict sensitivity or resistance to ICIs in NSCLC patients, thereby improving patient selection and treatment strategies. A secondary goal is to explore novel metabolic pathways as potential therapeutic targets, enhancing the efficacy of immunotherapy in both advanced and early-stage settings.
Results
The project is expected to deliver a comprehensive understanding of how metabolism in the TME influences the success of ICIs. Key outcomes include the identification of metabolic signatures correlating with clinical and pathological responses, improved biomarker-driven patient stratification, and the validation of new therapeutic approaches targeting metabolism to restore favorable immune responses. This will ultimately contribute to better prediction of treatment efficacy and the development of novel combination therapies in NSCLC.
Financial Support
PNRR, financed by Ministero della Salute
The total grant of the project is: € 950.000,00
The grant assigned to IFO – IRE is € 560.000,00
Other Institution involved: Policlinico P. Giaccone di Palermo
The funding resources are from the public notice 2° Avviso pubblico per la presentazione e selezione di progetti di ricerca da finanziare nell’ambito del PNRR sulle seguenti tematiche:
- Proof of concept (PoC);
- Tumori Rari (TR);
- Malattie Rare (MR);
- Malattie Croniche non Trasmissibili (MCnT) ad alto impatto sui sistemi sanitari e socio-assistenziali:
- Innovazione in campo diagnostico,
- Innovazione in campo terapeutico;
- Malattie Croniche non Trasmissibili (MCnT) ad alto impatto sui sistemi sanitari e socio-assistenziali:
- Fattori di rischio e prevenzione,
- Eziopatogenesi e meccanismi di malattia
Piano Nazionale di Ripresa e Resilienza - Missione M6 - Componente C2 - Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN finanziato dall’Unione europea - NextGenerationEU.